Offshore
Dimitry Nakhla | Babylon Capital® RT @DimitryNakhla: Two months ago I stated: “I’d be more interested in $TMO closer to $500💵 (8% below today’s price) where I can reasonably expect ~11% to ~12% CAGR while assuming a 23x - 24x end multiple, ensuring a margin…
𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐜𝐨𝐧𝐭𝐚𝐢𝐧𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐭𝐰𝐞𝐞𝐭 𝐡𝐚𝐬 𝐛𝐞𝐞𝐧 𝐨𝐛𝐭𝐚𝐢𝐧𝐞𝐝 𝐟𝐫𝐨𝐦 𝐬𝐨𝐮𝐫𝐜𝐞𝐬 𝐛𝐞𝐥𝐢𝐞𝐯𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐫𝐞𝐥𝐢𝐚𝐛𝐥𝐞, 𝐛𝐮𝐭 𝐢𝐬 𝐧𝐨𝐭 𝐠𝐮𝐚𝐫𝐚𝐧𝐭𝐞𝐞𝐝 𝐚𝐬 𝐭𝐨 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐞𝐧𝐞𝐬𝐬 𝐨𝐫 𝐚𝐜𝐜𝐮𝐫𝐚𝐜𝐲. - Dimitry Nakhla | Babylon Capital® tweet
Offshore
Photo
Stock Analysis Compilation
Bell AM on Core & Main $CNM US
Thesis: Core & Main is a mid-cap US industrial company well-positioned for growth through market share gains, mergers, and attractive valuation, promising solid double-digit earnings growth.
(Extract from their October letter) https://t.co/UeXo0EgCpo
tweet
Bell AM on Core & Main $CNM US
Thesis: Core & Main is a mid-cap US industrial company well-positioned for growth through market share gains, mergers, and attractive valuation, promising solid double-digit earnings growth.
(Extract from their October letter) https://t.co/UeXo0EgCpo
tweet
Offshore
Photo
Capital Employed
Q4 2024 Fund Letters Round-Up has just been published.
Some amazing annual performances. One fund achieved a 101% return 😲
https://t.co/Dndl7wcMwK https://t.co/unsqIkpdep
tweet
Q4 2024 Fund Letters Round-Up has just been published.
Some amazing annual performances. One fund achieved a 101% return 😲
https://t.co/Dndl7wcMwK https://t.co/unsqIkpdep
tweet
Offshore
Photo
Dimitry Nakhla | Babylon Capital®
$FICO is quietly down -20% from its highs https://t.co/aJtHu5h23U
tweet
$FICO is quietly down -20% from its highs https://t.co/aJtHu5h23U
tweet
Offshore
Photo
Offshore
Photo
InsideArbitrage
Johnson & Johnson $JNJ is in talks to acquire Intra-Cellular Therapies $ITCI, a biopharmaceutical company focused on treating central nervous system disorders - Bloomberg
A deal could be reached as soon as this week. While ongoing discussions may not lead to an agreement, other suitors could also emerge.
tweet
Johnson & Johnson $JNJ is in talks to acquire Intra-Cellular Therapies $ITCI, a biopharmaceutical company focused on treating central nervous system disorders - Bloomberg
A deal could be reached as soon as this week. While ongoing discussions may not lead to an agreement, other suitors could also emerge.
tweet
Offshore
Photo
Hidden Value Gems
Interesting points from co-CIO of Bridgewater Associates Karen Karniol-Tambur:
1⃣"US equities in aggregate need 9% annualised EPS growth to earn a normal return above bonds; the rest of the world needs only 2.5% annualised growth."
2⃣"Tech is priced for higher earnings than the rest of the S&P, though without much difference between Al and non-Al names."
3⃣"Other than India, EM equities require no EPS growth for a normal return above bonds."
#Stocks #StockMarket #Equity
tweet
Interesting points from co-CIO of Bridgewater Associates Karen Karniol-Tambur:
1⃣"US equities in aggregate need 9% annualised EPS growth to earn a normal return above bonds; the rest of the world needs only 2.5% annualised growth."
2⃣"Tech is priced for higher earnings than the rest of the S&P, though without much difference between Al and non-Al names."
3⃣"Other than India, EM equities require no EPS growth for a normal return above bonds."
#Stocks #StockMarket #Equity
tweet
Offshore
Photo
Stock Analysis Compilation
Baron Emerging Markets Fund on ISC Co $095340 KS
Thesis: ISC Co., Ltd. is poised to benefit from the shift to elastomer test sockets in semiconductor testing, leveraging its market dominance and strong growth linked to the AI and high-performance computing sectors.
(Extract from their Q3 letter)
tweet
Baron Emerging Markets Fund on ISC Co $095340 KS
Thesis: ISC Co., Ltd. is poised to benefit from the shift to elastomer test sockets in semiconductor testing, leveraging its market dominance and strong growth linked to the AI and high-performance computing sectors.
(Extract from their Q3 letter)
tweet
Offshore
Photo
Hidden Value Gems
"As 2024 began, the average return forecast for the S&P 500 was 7.4% by stock analysts and 1.3% by market strategists. The actual return, including dividends: 25.02%."
"For 2023, analysts predicted a 17.5% gain for the S&P 500; strategists, a 6.2% rise. The S&P realized a 26.3% increase, with dividends."
h/t @jasonzweigwsj
tweet
"As 2024 began, the average return forecast for the S&P 500 was 7.4% by stock analysts and 1.3% by market strategists. The actual return, including dividends: 25.02%."
"For 2023, analysts predicted a 17.5% gain for the S&P 500; strategists, a 6.2% rise. The S&P realized a 26.3% increase, with dividends."
h/t @jasonzweigwsj
tweet
Offshore
Photo
InsideArbitrage
Johnson & Johnson $JNJ to Acquire Intra-Cellular Therapies $ITCI for $14.6 Billion -
💊J&J will acquire all outstanding shares of Intra-Cellular for $132.00 per share in cash, representing a premium of 39.14% from the stock’s last close.
💊J&J expects to finance the deal, which is anticipated to close later this year, through a combination of cash on hand and debt.
tweet
Johnson & Johnson $JNJ to Acquire Intra-Cellular Therapies $ITCI for $14.6 Billion -
💊J&J will acquire all outstanding shares of Intra-Cellular for $132.00 per share in cash, representing a premium of 39.14% from the stock’s last close.
💊J&J expects to finance the deal, which is anticipated to close later this year, through a combination of cash on hand and debt.
tweet